tradingkey.logo

Soleno Therapeutics Inc

SLNO

80.320USD

-8.170-9.23%
Fechamento 07/10, 16:00ETCotações atrasadas em 15 min
3.67BValor de mercado
PerdaP/L TTM

Soleno Therapeutics Inc

80.320

-8.170-9.23%
Mais detalhes de Soleno Therapeutics Inc Empresa
Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
Informações da empresa
Código da empresaSLNO
Nome da EmpresaSoleno Therapeutics Inc
Data de listagemOct 23, 2014
Fundado em1999
CEODr. Anish Bhatnagar, M.D.
Número de funcionários92
Tipo de títulosOrdinary Share
Fim do ano fiscalOct 23
Endereço100 Marine Parkway, Suite 400
CidadeREDWOOD CITY
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal94065
Telefone16502138444
Sitehttps://soleno.life/
Código da empresaSLNO
Data de listagemOct 23, 2014
Fundado em1999
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. James H. (Jim) Mackaness
Mr. James H. (Jim) Mackaness
Chief Financial Officer
Chief Financial Officer
90.68K
+32.66%
Dr. Michael Huang, M.D.
Dr. Michael Huang, M.D.
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
36.82K
-11.07%
Ms. Kristen Yen
Ms. Kristen Yen
Senior Vice President - Global Clinical Operations and Patient Advocacy
Senior Vice President - Global Clinical Operations and Patient Advocacy
28.14K
-66.09%
Ms. Dawn Carter Bir
Ms. Dawn Carter Bir
Independent Director
Independent Director
16.99K
+30.70%
Mr. William G. (Bill) Harris
Mr. William G. (Bill) Harris
Independent Director
Independent Director
12.89K
+44.84%
Dr. Birgitte Volck, M.D., Ph.D.
Dr. Birgitte Volck, M.D., Ph.D.
Independent Director
Independent Director
11.04K
+56.65%
Dr. Andrew Sinclair, Ph.D.
Dr. Andrew Sinclair, Ph.D.
Independent Director
Independent Director
10.49K
+61.40%
Ms. Patricia C. Hirano
Ms. Patricia C. Hirano
Vice President - Regulatory Affairs
Vice President - Regulatory Affairs
6.81K
-36.00%
Dr. Anish Bhatnagar, M.D.
Dr. Anish Bhatnagar, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Ms. Meredith Manning
Ms. Meredith Manning
Chief Commercial Officer
Chief Commercial Officer
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. James H. (Jim) Mackaness
Mr. James H. (Jim) Mackaness
Chief Financial Officer
Chief Financial Officer
90.68K
+32.66%
Dr. Michael Huang, M.D.
Dr. Michael Huang, M.D.
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
36.82K
-11.07%
Ms. Kristen Yen
Ms. Kristen Yen
Senior Vice President - Global Clinical Operations and Patient Advocacy
Senior Vice President - Global Clinical Operations and Patient Advocacy
28.14K
-66.09%
Ms. Dawn Carter Bir
Ms. Dawn Carter Bir
Independent Director
Independent Director
16.99K
+30.70%
Mr. William G. (Bill) Harris
Mr. William G. (Bill) Harris
Independent Director
Independent Director
12.89K
+44.84%
Dr. Birgitte Volck, M.D., Ph.D.
Dr. Birgitte Volck, M.D., Ph.D.
Independent Director
Independent Director
11.04K
+56.65%
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 17 de mai
Atualizado em: sáb, 17 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Janus Henderson Investors
10.20%
Vivo Capital, LLC
8.85%
Adage Capital Management, L.P.
8.72%
Avoro Capital Advisors LLC
5.01%
T. Rowe Price Associates, Inc.
4.70%
Other
62.53%
Investidores
Investidores
Proporção
Janus Henderson Investors
10.20%
Vivo Capital, LLC
8.85%
Adage Capital Management, L.P.
8.72%
Avoro Capital Advisors LLC
5.01%
T. Rowe Price Associates, Inc.
4.70%
Other
62.53%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
33.33%
Hedge Fund
31.65%
Investment Advisor
26.64%
Venture Capital
12.54%
Private Equity
4.02%
Research Firm
2.73%
Individual Investor
1.92%
Bank and Trust
0.53%
Pension Fund
0.18%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
375
57.23M
113.56%
+142.75K
2025Q1
373
57.15M
113.59%
-442.82K
2024Q4
313
53.26M
117.76%
+3.04M
2024Q3
277
49.14M
121.09%
-377.00K
2024Q2
234
44.76M
117.95%
+4.14M
2024Q1
189
36.54M
114.10%
-1.05M
2023Q4
146
32.09M
102.81%
+3.37M
2023Q3
107
21.08M
166.08%
+14.34M
2023Q2
87
5.70M
63.31%
-1.46M
2023Q1
121
4.63M
57.04%
-249.13K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Janus Henderson Investors
5.14M
10.2%
-47.37K
-0.91%
Mar 31, 2025
Vivo Capital, LLC
4.46M
8.85%
-1.83M
-29.14%
Mar 31, 2025
Adage Capital Management, L.P.
4.39M
8.72%
+1.62M
+58.24%
Mar 31, 2025
Avoro Capital Advisors LLC
2.52M
5.01%
--
--
Mar 31, 2025
T. Rowe Price Associates, Inc.
2.37M
4.7%
+768.45K
+48.07%
Mar 31, 2025
Fidelity Management & Research Company LLC
2.12M
4.21%
+1.36M
+179.00%
Mar 31, 2025
The Vanguard Group, Inc.
1.86M
3.69%
-18.21K
-0.97%
Mar 31, 2025
Nantahala Capital Management, LLC
1.76M
3.49%
-2.17M
-55.28%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
1.72M
3.4%
-105.47K
-5.79%
Mar 31, 2025
Citadel Advisors LLC
1.58M
3.13%
+603.63K
+62.08%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 6 de jul
Atualizado em: dom, 6 de jul
Nome
Proporção
Harbor Health Care ETF
2.39%
Invesco Dorsey Wright SmallCap Momentum ETF
2.19%
SPDR S&P Biotech ETF
1.04%
Virtus LifeSci Biotech Clinical Trials ETF
0.98%
Direxion Daily S&P Biotech Bull 3X Shares
0.5%
JPMorgan Healthcare Leaders ETF
0.44%
First Trust Multi-Manager Small Cap Opportunities ETF
0.3%
Fidelity Fundamental Small-Mid Cap ETF
0.21%
Optimize Strategy Index ETF
0.19%
BNY Mellon US Small Cap Core Equity ETF
0.15%
Ver Mais
Harbor Health Care ETF
Proporção2.39%
Invesco Dorsey Wright SmallCap Momentum ETF
Proporção2.19%
SPDR S&P Biotech ETF
Proporção1.04%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.98%
Direxion Daily S&P Biotech Bull 3X Shares
Proporção0.5%
JPMorgan Healthcare Leaders ETF
Proporção0.44%
First Trust Multi-Manager Small Cap Opportunities ETF
Proporção0.3%
Fidelity Fundamental Small-Mid Cap ETF
Proporção0.21%
Optimize Strategy Index ETF
Proporção0.19%
BNY Mellon US Small Cap Core Equity ETF
Proporção0.15%
Dividendo
Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Aug 25, 2022
Merger
15<1
Aug 25, 2022
Merger
15<1
Aug 25, 2022
Merger
15<1
Aug 25, 2022
Merger
15<1
Data
Tipo
Proporção
Aug 25, 2022
Merger
15<1
Aug 25, 2022
Merger
15<1
Aug 25, 2022
Merger
15<1
Aug 25, 2022
Merger
15<1
KeyAI